WeVote
Log In

Bill

Bill

HB 4626

Relating to the establishment of a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine

2026 Regular Session Introduced by Ryan Browning and 6 co-sponsors

WV would create a state grant program to fund FDA-regulated ibogaine clinical trials.

Vetoed by Governor 4/1/2026
#health
0
WeVote Research Nonpartisan
Bill Summary · HB 4626

Overview

HB 4626 (West Virginia, 2026) proposes establishing a grant program to fund United States Food and Drug Administration (FDA) drug development trials that use ibogaine. The bill outlines the creation of a state-funded mechanism to support specific clinical research activities related to ibogaine, with aims tied to drug development and potential therapeutic applications.

Primary purpose and intent

  • Create a dedicated grant program within the state to support FDA drug development trials that involve ibogaine.
  • Facilitate funding for research activities, infrastructure, or other eligible expenses necessary to conduct FDA-approved ibogaine clinical trials.
  • Seek to advance ibogaine-related drug development through publicly supported clinical research, with the objective of aligning state resources with federal regulatory processes.

Key provisions and changes

  • Establishment of a grant program:
    • The bill would authorize the creation of a program to award grants to qualified entities (likely researchers, institutions, or sponsors) conducting FDA-regulated ibogaine trials.
  • Eligibility and administration:
    • The bill would specify who can apply (e.g., research institutions, hospitals, or sponsored clinical trial entities) and under what criteria grants are awarded.
    • Likely outlines the administrative body responsible for administering the program, application procedures, reporting requirements, and compliance standards.
  • Funding and appropriation:
    • The bill would establish sourcing or appropriation mechanics for the grant funds (e.g., state budget allocation, fund balances, or other funding streams).
    • May include caps, duration, and renewal terms for grant awards.
  • Scope of trials:
    • Explicitly ties funding to FDA-regulated ibogaine drug development trials, potentially limiting to certain indications or trial phases (e.g., Phase I–III) as defined by FDA guidelines.
  • Accountability and reporting:
    • Provisions for progress reporting, outcome measures, auditing, and transparency to ensure proper use of funds and alignment with statutory purposes.
  • Related regulatory compliance:
    • Likely references adherence to federal research regulations, patient safety protocols, and ethical standards in clinical trials.

Who would be affected

  • Eligible grant applicants:
    • Research institutions, universities, medical centers, or clinical trial sponsors pursuing FDA ibogaine trials.
  • State financial administration:
    • The Department/agency designated to administer the grant program would oversee awards, monitoring, and reporting.
  • Recipients and trial participants:
    • Potential injured or affected populations who would participate in trials funded under the program, subject to FDA and IRB approvals.

Procedural and timeline aspects

  • Legislative history highlights:
    • Introduced in January 2026.
    • Passed House in late January 2026 and sent to Senate; reflected in multiple readings and committee actions.
    • Senate passed on March 12, 2026 (Roll No. 487) and communicated back to the House.
    • The bill underwent veto by the Governor; action history shows a veto on April 1, 2026, with subsequent veto entries and communications noted.
  • Veto status:
    • The governor vetoed the bill (noted as 4/1/2026). If a veto is sustained, the bill would fail to become law unless overridden by legislative action.
  • Next steps:
    • If vetoed and not overridden, the program would not be established.
    • If the legislature overrides the veto, the program could proceed to implementation per the enacted provisions and any updated statutory language.

Notes and context

  • The bill centers on funding experimental or investigational use of ibogaine in FDA-approved trials, which involves complex regulatory considerations given ibogaine’s status in many jurisdictions and its pharmaceutical development pathways.
  • The presence of co-sponsors suggests cross-chamber and bipartisan engagement to advance the concept, though final passage depended on gubernatorial action.
  • Specifics such as grant amounts, eligible trial types, match requirements (if any), and funding duration would be determined in the enacted language and accompanying administrative rules.

If you’d like, I can tailor this summary to emphasize particular sections (eligibility criteria, funding mechanics, or oversight provisions) once you provide the final enacted text or more detailed bill language.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.